Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to cytotoxic / biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allows for sensitive discrimination between healthy and diseased tissue.
With six marketed drugs(1), and 246 ongoing clinical trials(2), ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications.
For Analytical Development of your ADC, SBH Sciences offers multiple state-of-the-art platforms, including cell-based assays, Simple Western Jess instrument, and Flow Cytometry.
Numerous analytes must be measured for the quantitative assessment of ADCs in serum or plasma:
Ligand Binding Assays (ELISA) are ideally suited for the bioanalysis of ADCs and their component parts (except for free drug). For pre-clinical or clinical sample (plasma or serum) analysis, we can provide:
SBH Sciences has extensive experience developing assays for immunogenicity, using a multi-tiered approach which includes screening, confirmatory, tittering, and neutralization. Our scientists understand the complexity of ADCs and the development of assays required to measure total drug conjugates and naked molecules for PK analysis.
SBH Sciences is determined to maintain the highest standards and deliver the highest quality services. We welcome you to communicate with us about your specific research requirements.
1. The six marketed ADCs are:
(a) Brentuximab vedotin (Adcetris, Seattle Genetics, Millennium/Takeda),
(b) Trastuzumab emtansine (Kadcyla, Genentech, Roche),
(c) Inotuzumab ozogamicin (Besponsa, Pfizer/Wyeth),
(d) Polatuzumab vedotin-piiq (Polivy, Genentech, Roche),
(e) Enfortumab vedotin (Padcev, Astellas/Seattle Genetics),
(f) Trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo)
2. According to ClinicalTrials.gov, Feb 25, 2020